In gliosarcoma (WHO grade IV), only half of the samples displayed focal GAL-immunoreactivity (15–70% of tumor cells, Figure 5D), whereas all giant cell glioblastomas (WHO grade IV) revealed focal GAL-immunoreactivity (35–80% of tumor cells; Figure 5G). This evidence concerns the gene GAL and giant cell glioblastoma.